CHARACTERIZATION OF VASOACTIVE-INTESTINAL-PEPTIDE RECEPTORS IN HUMAN LIVER

被引:18
|
作者
RODRIGUEZHENCHE, N [1 ]
RODRIGUEZPENA, MS [1 ]
GUIJARRO, LG [1 ]
PRIETO, JC [1 ]
机构
[1] UNIV ALCALA DE HENARES, DEPT BIOQUIM & BIOL MOLEC, UNIDAD NEUROENDOCRINOL MOLEC, E-28871 ALCALA DE HENARES, SPAIN
来源
关键词
VASOACTIVE INTESTINAL PEPTIDE (VIP); VIP RECEPTOR; G PROTEIN; ADENYLYL CYCLASE; HUMAN LIVER;
D O I
10.1016/0167-4889(94)90013-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The stoichiometric, pharmacological and molecular properties of vasoactive intestinal peptide (VIP) receptors have been analyzed in human liver membranes and compared in parallel with those in rat liver membranes. The binding of [I-125]VIP was rapid, saturable and specific. The stoichometric data indicated the presence of two classes of binding sites in both human and rat liver membranes with K-d values of 0.22 (human) and 0.20 (rat) nM for the high-affinity site, and 27.3 (human) and 3.6 (rat) nM for the low-affinity site. Tracer binding was displaced by structurally related peptides with an order of potency: VIP = PACAP-27 > helodermin > secretin in human liver, and VIP = PACAP-27 = helodermin > secretin in rat liver. GTP inhibited [I-125]VIP binding in a dose-dependent manner suggesting the involvement of a G protein in the signal transduction pathway. Cross-linking experiments revealed an apparent molecular mass for the VIP-receptor complex that was 67500 +/- 2700 and 50500 +/- 900 in human and rat preparations, respectively. VIP receptors were functional, since VIP stimulated adenylyl cyclase activity in a dose dependent manner with similar efficacy but different potency in human (ED(50) = 1.2 nM) and rat (ED(50) = 5.8 nM) liver membranes.
引用
收藏
页码:193 / 198
页数:6
相关论文
共 50 条
  • [31] VASOACTIVE-INTESTINAL-PEPTIDE RECEPTOR EXPRESSION ON HUMAN LYMPHOBLASTS
    ODORISIO, MS
    SHANNON, BT
    MULNE, AF
    ZWICK, D
    GROSSMAN, NJ
    RUYMANN, FB
    AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1992, 14 (02): : 144 - 150
  • [32] VASOACTIVE-INTESTINAL-PEPTIDE IN HUMAN NASAL-MUCOSA
    BARANIUK, JN
    LUNDGREN, JD
    OKAYAMA, M
    MULLOL, J
    MERIDA, M
    SHELHAMER, JH
    KALINER, MA
    JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (03): : 825 - 831
  • [33] IMMUNOHISTOCHEMICAL LOCALIZATION OF RECEPTORS FOR VASOACTIVE-INTESTINAL-PEPTIDE AND SUBSTANCE-P IN HUMAN TRACHEA
    FISCHER, A
    KUMMER, W
    COURAUD, JY
    ADLER, D
    BRANSCHEID, D
    HEYM, C
    LABORATORY INVESTIGATION, 1992, 67 (03) : 387 - 393
  • [34] CLONING AND EXPRESSION OF THE HUMAN VASOACTIVE-INTESTINAL-PEPTIDE RECEPTOR
    SREEDHARAN, SP
    ROBICHON, A
    PETERSON, KE
    GOETZL, EJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) : 4986 - 4990
  • [35] EFFECT OF VASOACTIVE-INTESTINAL-PEPTIDE AND THE DISTRIBUTION OF RECEPTORS IN HUMAN EPICARDIAL CORONARY-ARTERIES
    LUU, TN
    DASHWOOD, MR
    ONEIL, GS
    CHESTER, AH
    MUDDLE, JR
    YACOUB, MH
    CORONARY ARTERY DISEASE, 1992, 3 (03) : 231 - 235
  • [36] Characterization of vasoactive intestinal peptide receptors on human megakaryocytes and platelets
    Park, SK
    Olson, TA
    Ercal, N
    Summers, M
    ODorisio, MS
    BLOOD, 1996, 87 (11) : 4629 - 4635
  • [37] INTERACTION OF A BOVINE THYMIC PEPTIDE EXTRACT WITH VASOACTIVE-INTESTINAL-PEPTIDE (VIP) RECEPTORS
    GUERRERO, JM
    GOBERNA, R
    MOLINERO, P
    JIMENEZ, J
    CALVO, JR
    BIOSCIENCE REPORTS, 1986, 6 (06) : 579 - 584
  • [38] MODULATORY EFFECTS OF SOMATOSTATIN AND VASOACTIVE-INTESTINAL-PEPTIDE ON HUMAN INTESTINAL LYMPHOCYTES
    PALLONE, F
    FAIS, S
    ANNIBALE, B
    BOIRIVANT, M
    MORACE, S
    DELLEFAVE, G
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 594 : 408 - 410
  • [39] RECEPTORS FOR VASOACTIVE-INTESTINAL-PEPTIDE ON MURINE LYMPHOCYTES TURN OVER RAPIDLY
    OTTAWAY, CA
    JOURNAL OF NEUROIMMUNOLOGY, 1992, 38 (03) : 241 - 254
  • [40] SUPERACTIVE LIPOPHILIC PEPTIDES DISCRIMINATE MULTIPLE VASOACTIVE-INTESTINAL-PEPTIDE RECEPTORS
    GOZES, I
    LILLING, G
    GLAZER, R
    TICHER, A
    ASHKENAZI, IE
    DAVIDSON, A
    RUBINRAUT, S
    FRIDKIN, M
    BRENNEMAN, DE
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1995, 273 (01): : 161 - 167